Mydecine Closes Sale of Mindleap for $3.6 million

Starting this summer, we began reporting on the apparent troubles over at Mydecine. The company, once an underdog favorite with an interesting pipeline and clinical trial deals with Johns Hopkins, began a slow decline that caused many commentators to predict that the end was near.

The majority of the board resigned, cash reserves dwindled to dangerous levels, and there was a reverse stock split.

Yet in September, Mydecine said it’s cutting costs and narrowing its scope, focusing on its drug development programs (which do have potential) — and they signed a letter of intent for the sale of its digital technology subsidiary, Mindleap Health to PanGenomic Health for $4,000,000.

This week the sale was closed. PanGenomic acquired all of Mindleap’s outstanding shares for a purchase price of C$3,600,000 (payable by the issuance of units of PanGenomic at a price of C$0.20 per Unit).

Are you looking for an online shop where you can always find high-quality THC gummies and other hemp products? We invite you to browse the...

 CBD / Featured

Cannaffex offers Premium CBD products sourced organically from farms in beautiful British Columbia, Canada. All products we offer are THC-FREE and contain only organic hemp...

 CBD / Featured

Best Canadian Online Dispensary to Buy Your THC & CBD Edibles. Our goal is to provide everyone that wants to experience Edibles to have a...

 Edibles / Featured

Sydney Vaporizers is the premium online platform to service the needs of the vaping community across Sydney, Brisbane, Melbourne, Canberra, Hobart, Adelaide, Darwin and every...

 Vapes and Carts / Featured

Page 1 of 4